Gorlin syndrome-induced pluripotent stem cells form medulloblastoma with loss of heterozygosity in PTCH1

Aging (Albany NY). 2020 May 21;12(10):9935-9947. doi: 10.18632/aging.103258. Epub 2020 May 21.

Abstract

Gorlin syndrome is a rare autosomal dominant hereditary disease with a high incidence of tumors such as basal cell carcinoma and medulloblastoma. Disease-specific induced pluripotent stem cells (iPSCs) and an animal model have been used to analyze disease pathogenesis. In this study, we generated iPSCs derived from fibroblasts of four patients with Gorlin syndrome (Gln-iPSCs) with heterozygous mutations of the PTCH1 gene. Gln-iPSCs from the four patients developed into medulloblastoma, a manifestation of Gorlin syndrome, in 100% (four out of four), of teratomas after implantation into immunodeficient mice, but none (0/584) of the other iPSC-teratomas did so. One of the medulloblastomas showed loss of heterozygosity in the PTCH1 gene while the benign teratoma, i.e. the non-medulloblastoma portion, did not, indicating a close clinical correlation between tumorigenesis in Gorlin syndrome patients and Gln-iPSCs.

Keywords: Gorlin syndrome; PTCH1; heterozygosity; induced pluripotent stem cells; medulloblastoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Basal Cell Nevus Syndrome / genetics*
  • Cerebellar Neoplasms / genetics*
  • Child
  • Female
  • Humans
  • Induced Pluripotent Stem Cells
  • Loss of Heterozygosity / genetics*
  • Male
  • Medulloblastoma / genetics*
  • Patched-1 Receptor / genetics*

Substances

  • PTCH1 protein, human
  • Patched-1 Receptor